血管能抑素canstatin治疗肿瘤研究进展  

Research progress of treatment on tumor with canstatin

作　　者：石磊(综述) 陈平(审校) 

机构地区：[1]扬州大学临床医学院胃肠外科,225001

出　　处：《国际肿瘤学杂志》2009年第3期184-186,共3页Journal of International Oncology

摘　　要：血管能抑素canstatin是一种来源于Ⅳ型胶原α2链非胶原（NC1）区的血管生成和肿瘤生长内源性抑制因子。相比放疗、化疗等传统的肿瘤治疗方法，canstatin具有特异性高，不易产生抗药性等特点。临床研究表明，canstatin联合抑制肿瘤血管生成的其它疗法协同作用，在未来肿瘤的治疗中有着广阔的应用前景。Angiogenesis is a hallmark of tumor development and metastasis. Antiangiogenesis therapy takes the tumor vascular endothelial cells as the target so as to bring out a new modality for cancer treatment. Canstatin is a novel endogenous inhibitor of angiogenesis and tumor growth, derived from the C-terminal globular non-collagenous （ NC1 ）, domain of the α2 chain of type IV collagen. Compared with conventional methods for cancer treatment, such as the radiotherapy and the chemotherapy, canstatin has high specificity, is not easy to form the antibiotic characteristic. The fingings of clinical research show that there will be a broader application prospect for treatment of cancer when eanstatin is combined with other therapies of interdicting tumor angiogenesis.

关 键 词：血管生成抑制剂 肿瘤 凋亡 

分 类 号：R730.23[医药卫生—肿瘤] R979.1[医药卫生—临床医学]